AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, M. R.
Right arrow Articles by Kopple, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, M. R.
Right arrow Articles by Kopple, J. D.
Agricola
Right arrow Articles by Jones, M. R.
Right arrow Articles by Kopple, J. D.

American Journal of Clinical Nutrition, Vol 31, 1660-1664, Copyright © 1978 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Valine metabolism in normal and chronically uremic man

MR Jones and JD Kopple

Valine metabolism was investigated in five normal and three nondialyzed chronically uremic subjects eating 40 +/- SEM 1 and 53 (range 40 to 80) protein diets respectively, in a metabolic research unit. Subjects were injected iv with a tracer dose of L-valine-1-14C while they fasted, and specific activity of plasma valine-14C and expiration of 14CO2 were monitored for two hours. Plasma valine was significantly lower in the uremic patients than in the normal subjects (P less than 0.05). In the uremic patients, specific activity of plasma valine fell less rapidly and remained higher, and expiration of 14CO2 was not different from normal subjects. A two-pool model for valine metabolism was derived which indicated that in uremic patients there was a significant decrease in both valine pools and in the rate of irreversible loss, i.e., valine incorporated into larger molecules, degraded, or excreted. Valine degradation was estimated to be decreased in the uremic patients.


This article has been cited by other articles:


Home page
 J. Nutr.Home page
N. J. M. Cano, D. Fouque, and X. M. Leverve
Application of Branched-Chain Amino Acids in Human Pathological States: Renal Failure
J. Nutr., January 1, 2006; 136(1): 299S - 307S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by The American Society for Nutrition